Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Breast Neoplasms × Capsules × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 3 Thyroid Nodule 1 Thyroid Neoplasms 1 Thyroid Diseases 1 Solid Tumors 1 Small Cell Lung Carcinoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Parathyroid Neoplasms 1 Parathyroid Diseases 1 Opioid-Related Disorders 1 Myeloproliferative Disorders 1 Myelodysplastic Syndromes 1 Leukemia, Myeloid, Acute 1 Leukemia, Biphenotypic, Acute 1 Goiter 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Agnosia 1

Interventions

Trastuzumab 350 Paclitaxel 333 Cyclophosphamide 315 Docetaxel 291 Doxorubicin 180 Capecitabine 180 Letrozole 165 Tamoxifen 145 Bevacizumab 123 Carboplatin 119 Fulvestrant 118 exemestane 111 Lapatinib 111 Anastrozole 111 Radiotherapy 104 Epirubicin 104 Gemcitabine 97 palbociclib 83 Fluorouracil 77 Vinorelbine 76 Exercise 76 Surveys and Questionnaires 70 pertuzumab 68 Filgrastim 64 Albumin-Bound Paclitaxel 64 Magnetic Resonance Spectroscopy 56 eribulin 55 Everolimus 52 Blood Specimen Collection 51 Zoledronic Acid 50

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03262935 2023-10-19

TULIP

Byondis B.V.

Phase 3 Completed

437 enrolled 17 charts

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡